Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma | Nature Medicine
Neoadjuvant combination treatment with nivolumab and ipilimumab in patients with high-risk melanoma results in higher response rates than nivolumab monotherapy and warrants future optimization of dosing regimens to preserve efficacy while limiting toxicity.
Data availability The authors declare that the data supporting the findings of this study are available within the paper and its Supplementary Information. Whole-exome sequencing, T cell receptor sequencing and Nanostring digital spatial profiling data are available from the European Genome-phenome Archive under accession number EGAS00001003178. Change history 25 October 2018 In the version of this article originally published, there was an error in Fig. 1. In the neoadjuvant phase column, the n values for arms A and B were both reported to be 20. The n values for arms A and B were…
saved by
related reading
- Immunotherapy in pediatric malignancies: current status and future perspectives - PMCncbi.nlm.nih.gov
- Cancer Study Links COVID Shots to Longer Survivalmedpagetoday.com
- Going Founder Mode On Cancer - by Elliot Hershbergcenturyofbio.com
- Overview of toxicities associated with immune checkpoint inhibitorsuptodate.com
- Research advances in treatment strategies for breast cancer liver metastases: A comprehensive review - PMCpmc.ncbi.nlm.nih.gov
- Cancer cells educate natural killer cells to a metastasis-promoting cell state - PMCpmc.ncbi.nlm.nih.gov
- Medical Research Council (MRC)ukri.org
- Warpspeed — Forecastswarpspeed.sh
- Immunotherapy for Cancer - NCIcancer.gov
- Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexatencbi.nlm.nih.gov
- Has pancreatic cancer met its match?worksinprogress.co
- Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer | Naturenature.com